Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

News Daily News

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

Caitlin E. Cox

July 14, 2025

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Features

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Michael O'Riordan

January 17, 2022

News Features

Roughly 80% of ESC Guideline Writers Have Financial COIs

Michael O'Riordan

April 01, 2021

News Daily News

FDA Advisors Unconvinced by Lutonix BTK Drug-Coated Balloon

L.A. McKeown

February 18, 2021

News Conference News STS 2020

TAVR Tussle at US Surgery Meeting Threatens to Widen Surgeon-Cardiologist Wedge

Yael L. Maxwell

January 29, 2020

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

News Daily News

FDA Expands TAVR Indication to Low-Risk Patients

Michael O'Riordan

August 16, 2019

News Daily News

Details in Print for DanGer Design as Impella AMICS RCT Expands From Denmark to Germany

Caitlin E. Cox

May 14, 2019

News Daily News

‘The Bleeding Edge’ Documentary, Tackling Medical Device Regulation, Spurs Diverse Cardiology Reactions

Yael L. Maxwell

August 17, 2018

News Daily News

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

Todd Neale

May 04, 2018

News Daily News

FDA Clears Sentinel Cerebral Protection Device for Use During TAVR

Shelley Wood

June 05, 2017

News Daily News

Rapid Rule-Out Strategy With High-Sensitivity Troponin Shows Promise Ahead of US Commercial Availability of Test

L.A. McKeown

April 17, 2017

News Daily News

FDA Gives Thumbs Up to Side Branch Stent for Bifurcation Lesions

Todd Neale

March 06, 2017

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

Advertisement

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Roughly 80% of ESC Guideline Writers Have Financial COIs

FDA Advisors Unconvinced by Lutonix BTK Drug-Coated Balloon

TAVR Tussle at US Surgery Meeting Threatens to Widen Surgeon-Cardiologist Wedge

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

FDA Expands TAVR Indication to Low-Risk Patients

Details in Print for DanGer Design as Impella AMICS RCT Expands From Denmark to Germany

‘The Bleeding Edge’ Documentary, Tackling Medical Device Regulation, Spurs Diverse Cardiology Reactions

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

FDA Clears Sentinel Cerebral Protection Device for Use During TAVR

Rapid Rule-Out Strategy With High-Sensitivity Troponin Shows Promise Ahead of US Commercial Availability of Test

FDA Gives Thumbs Up to Side Branch Stent for Bifurcation Lesions

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content